Tim Maughan

20.2k total citations · 4 hit papers
243 papers, 7.7k citations indexed

About

Tim Maughan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Tim Maughan has authored 243 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 174 papers in Oncology, 91 papers in Pulmonary and Respiratory Medicine and 45 papers in Pathology and Forensic Medicine. Recurrent topics in Tim Maughan's work include Colorectal Cancer Treatments and Studies (121 papers), Gastric Cancer Management and Outcomes (42 papers) and Genetic factors in colorectal cancer (40 papers). Tim Maughan is often cited by papers focused on Colorectal Cancer Treatments and Studies (121 papers), Gastric Cancer Management and Outcomes (42 papers) and Genetic factors in colorectal cancer (40 papers). Tim Maughan collaborates with scholars based in United Kingdom, United States and Italy. Tim Maughan's co-authors include Michel Seymour, Richard Adams, Richard Kaplan, David J. Fisher, Stephen Falk, Gareth Griffiths, Mahesh Parmar, Angela Meade, Harpreet Wasan and David Sebag‐Montefiore and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Tim Maughan

233 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

2014 534 citations Sabine Venderbosch, Irıs D. Nagtegaal et al. Clinical Cancer Research profile →
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial

2013 459 citations David Cunningham, Tim Maughan et al. The Lancet Oncology profile →
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

2016 434 citations Tim Maughan, Richard Adams et al. The Lancet Oncology profile →
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

2025 34 citations Scott Kopetz, Takayuki Yoshino et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tim Maughan United Kingdom	43	5.0k	2.5k	2.4k	1.4k	1.1k	243	7.7k
Per Pfeiffer Denmark	45	3.9k 0.8×	1.8k 0.7×	1.9k 0.8×	800 0.6×	1.2k 1.1×	302	6.3k
Fausto Petrelli Italy	50	5.9k 1.2×	3.2k 1.3×	2.3k 1.0×	1.2k 0.9×	1.7k 1.5×	280	9.1k
Alberto Zaniboni Italy	40	6.3k 1.3×	2.5k 1.0×	1.5k 0.6×	1.9k 1.4×	1.5k 1.4×	301	8.1k
Young Suk Park South Korea	41	4.0k 0.8×	2.3k 0.9×	1.9k 0.8×	738 0.5×	1.1k 1.0×	227	6.3k
Miriam Koopman Netherlands	41	5.7k 1.1×	1.9k 0.8×	1.8k 0.8×	2.0k 1.5×	1.3k 1.2×	222	8.0k
Enrico Cortesi Italy	41	4.7k 0.9×	2.5k 1.0×	1.4k 0.6×	783 0.6×	1.5k 1.3×	266	7.2k
Axel Hinke Germany	40	5.6k 1.1×	3.1k 1.3×	2.0k 0.9×	1.7k 1.2×	1.4k 1.3×	189	8.5k
Johannes H.W. de Wilt Netherlands	51	5.9k 1.2×	2.1k 0.9×	4.2k 1.8×	1.1k 0.8×	802 0.7×	320	9.3k
Bruno Landi France	26	5.9k 1.2×	2.9k 1.2×	1.7k 0.7×	1.9k 1.4×	1.5k 1.4×	70	8.3k
Paul Ruff South Africa	32	6.4k 1.3×	2.6k 1.1×	1.3k 0.5×	1.8k 1.3×	1.2k 1.1×	155	8.9k

Countries citing papers authored by Tim Maughan

Since Specialization

Citations

This map shows the geographic impact of Tim Maughan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Maughan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Maughan more than expected).

Fields of papers citing papers by Tim Maughan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Maughan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Maughan. The network helps show where Tim Maughan may publish in the future.

Co-authorship network of co-authors of Tim Maughan

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Maughan. A scholar is included among the top collaborators of Tim Maughan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Maughan. Tim Maughan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Domingo, Enric, Juan Fernández‐Tajes, Kathryn A.F. Pennel, et al.. (2025). Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis. Molecular Cancer Research. 23(4). 300–312. 1 indexed citations

Kopetz, Scott, Takayuki Yoshino, Eric Van Cutsem, et al.. (2025). Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nature Medicine. 31(3). 901–908. 34 indexed citations breakdown →

O’Cathail, Séan M., Meng Qiao, Richard Adams, et al.. (2023). A Phase 1 Trial of the Safety, Tolerability, and Biological Effects of Intravenous Enadenotucirev (EnAd), a Novel Oncolytic Virus, in Combination with Chemoradiotherapy in Locally Advanced Rectal Cancer (CEDAR). International Journal of Radiation Oncology*Biology*Physics. 117(2). e329–e330. 1 indexed citations

Heuvel, Frank Van den, F. Fiorini, Mark A. Hill, et al.. (2022). Using oxygen dose histograms to quantify voxelised ultra-high dose rate (FLASH) effects in multiple radiation modalities. Physics in Medicine and Biology. 67(12). 125001–125001. 4 indexed citations

Heuvel, Frank Van den, et al.. (2021). Incorporating oxygenation levels in analytical DNA-damage models—quantifying the oxygen fixation mechanism. Physics in Medicine and Biology. 66(14). 145005–145005. 5 indexed citations

Dhawan, Andrew, Alessandro Barberis, Enric Domingo, et al.. (2019). Guidelines for using sigQC for systematic evaluation of gene signatures. Nature Protocols. 14(5). 1377–1400. 20 indexed citations

Barber, Paul R., Gregory Weitsman, Katherine Lawler, et al.. (2019). HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial. JNCI Journal of the National Cancer Institute. 112(9). 944–954. 8 indexed citations

Maughan, Tim, Richard Kaplan, Philip Law, et al.. (2019). Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants. European Journal of Cancer. 124. 56–63. 6 indexed citations

Sobrero, Alberto, Axel Grothey, Timothy Iveson, et al.. (2018). The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?. Annals of Oncology. 29(5). 1099–1107. 27 indexed citations

10.

Richman, Susan D., Simon Gollins, Peter Stewart, et al.. (2018). Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies. The Journal of Pathology. 245(1). 19–28. 40 indexed citations

11.

Adams, Richard, Ewan Brown, Louise Brown, et al.. (2017). Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial. The Lancet. Gastroenterology & hepatology. 3(3). 162–171. 37 indexed citations

12.

Richman, Susan D., Richard Adams, Ewan Brown, et al.. (2017). FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, BRAF and PIK3CA. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 243. 1 indexed citations

13.

Smith, Christopher G., et al.. (2016). BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer. Clinical Cancer Research. 23(11). 2742–2749. 35 indexed citations

14.

Smith, Christopher G., David J. Fisher, Rebecca Harris, et al.. (2015). Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival. Clinical Cancer Research. 21(15). 3453–3461. 16 indexed citations

15.

Venderbosch, Sabine, Irıs D. Nagtegaal, Tim Maughan, et al.. (2014). Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clinical Cancer Research. 20(20). 5322–5330. 534 indexed citations breakdown →

16.

Smith, Christopher G., David J. Fisher, Bart Claes, et al.. (2013). Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab. Clinical Cancer Research. 19(15). 4104–4113. 86 indexed citations

17.

Crosby, T., Chris Hurt, Stephen Falk, et al.. (2013). Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. The Lancet Oncology. 14(7). 627–637. 272 indexed citations

18.

Maughan, Tim. (2011). The treatment of patients with low tumour burden and/or slow growing disease. European Journal of Cancer. 47. S67–S75. 1 indexed citations

19.

Bramhall, Simon R., M T Hallissey, J Whiting, et al.. (2002). Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. British Journal of Cancer. 86(12). 1864–1870. 199 indexed citations

20.

Maughan, Tim, et al.. (1990). Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (RO 03-8799) and etanidazole (SR 2508). International Journal of Radiation Oncology*Biology*Physics. 18(5). 1151–1156. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact